It’s taken five months, but the FDA has finally issued its first untitled letter of the year for promotional infractions. The agency's watchdogs scolded Orexigen Therapeutics for infractions in a TV commercial for weight loss drug Contrave.
Meet Orexigen Therapeutics, Inc. (NASDAQ: OREX), a micro-cap biopharmaceutical company delivering one of the strongest stock market performances of 2017 so far. After losing almost 90 percent of its value over 2016, shares have recuperated more...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.